Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125 Brachytherapy for Choroidal and Ciliary Body Melanoma.

IF 0.4 Q4 OPHTHALMOLOGY

Open Ophthalmology Journal Pub Date : 2015-06-26 eCollection Date: 2015-01-01 DOI:10.2174/1874364101509010131

Irena Tsui, Robert M Beardsley, Tara A McCannel, Scott C Oliver, Melissa W Chun, Steve P Lee, Phillip E Chow, Nzhde Agazaryan, Fei Yu, Bradley R Straatsma

{"title":"Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125 Brachytherapy for Choroidal and Ciliary Body Melanoma.","authors":"Irena Tsui, Robert M Beardsley, Tara A McCannel, Scott C Oliver, Melissa W Chun, Steve P Lee, Phillip E Chow, Nzhde Agazaryan, Fei Yu, Bradley R Straatsma","doi":"10.2174/1874364101509010131","DOIUrl":null,"url":null,"abstract":"Purpose: To report visual acuity, contrast sensitivity and color vision prior to, 1 year after, 2 years after and 3 years after iodine-125 brachytherapy for choroidal and ciliary body melanoma (CCM).Design: Prospective interventional case series.Participants: Thirty-seven patients (37 eyes) with CCM.Methods: Patients had best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, Pelli-Robson contrast sensitivity and Hardy-Rand-Rittler color vision measurement; comprehensive ophthalmology examination; optical coherence tomography; and ultrasonography at baseline prior to, 1 year after, 2 years after and 3 years after I-125 brachytherapy.Main outcome measures: Visual acuity, contrast sensitivity and color vision prior to, 1 year after, 2 years after and 3 years after brachytherapy.Results: Nineteen (19) men and 18 women with mean age of 58 years (SD 13, range 30-78) prior to, 1 year after, 2 years after and 3 years after brachytherapy had mean best-corrected visual acuity of 77 letters (20/32), 65 letters (20/50), 56 letters (20/80) and 47 letters (20/125); contrast sensitivity of 30, 26, 22 and 19 letters; color vision of 26, 20, 17 and 14 test figures, respectively. Decrease in visual acuity, contrast sensitivity and color vision was statistically significant from baseline at 1 year, 2 years, and 3 years after brachytherapy. Decreased acuity at 3 years was associated with mid-choroid and macula melanoma location, ≥ 4.1 mm melanoma height, radiation maculopathy and radiation optic neuropathy.Conclusion: 1, 2 and 3 years after brachytherapy, eyes with CCM had significantly decreased visual acuity, contrast sensitivity and color vision.","PeriodicalId":46347,"journal":{"name":"Open Ophthalmology Journal","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2015-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/ce/TOOPHTJ-9-131.PMC4541296.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Ophthalmology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874364101509010131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Purpose: To report visual acuity, contrast sensitivity and color vision prior to, 1 year after, 2 years after and 3 years after iodine-125 brachytherapy for choroidal and ciliary body melanoma (CCM).

Design: Prospective interventional case series.

Participants: Thirty-seven patients (37 eyes) with CCM.

Methods: Patients had best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, Pelli-Robson contrast sensitivity and Hardy-Rand-Rittler color vision measurement; comprehensive ophthalmology examination; optical coherence tomography; and ultrasonography at baseline prior to, 1 year after, 2 years after and 3 years after I-125 brachytherapy.

Main outcome measures: Visual acuity, contrast sensitivity and color vision prior to, 1 year after, 2 years after and 3 years after brachytherapy.

Results: Nineteen (19) men and 18 women with mean age of 58 years (SD 13, range 30-78) prior to, 1 year after, 2 years after and 3 years after brachytherapy had mean best-corrected visual acuity of 77 letters (20/32), 65 letters (20/50), 56 letters (20/80) and 47 letters (20/125); contrast sensitivity of 30, 26, 22 and 19 letters; color vision of 26, 20, 17 and 14 test figures, respectively. Decrease in visual acuity, contrast sensitivity and color vision was statistically significant from baseline at 1 year, 2 years, and 3 years after brachytherapy. Decreased acuity at 3 years was associated with mid-choroid and macula melanoma location, ≥ 4.1 mm melanoma height, radiation maculopathy and radiation optic neuropathy.

Conclusion: 1, 2 and 3 years after brachytherapy, eyes with CCM had significantly decreased visual acuity, contrast sensitivity and color vision.

查看原文本刊更多论文

碘125近距离放射治疗脉络膜和睫状体黑色素瘤3年后的视力、对比敏感度和色觉。

目的:报告碘125近距离放射治疗脉络膜和睫状体黑色素瘤(CCM)前、后1年、后2年和后3年的视力、对比敏感度和色觉。设计:前瞻性介入病例系列。参与者:37例(37眼)CCM患者。方法:采用最佳矫正早期治疗糖尿病视网膜病变研究(ETDRS)患者的视力、Pelli-Robson对比敏感度和Hardy-Rand-Rittler色觉测量;眼科综合检查;光学相干层析;以及I-125近距离治疗前、治疗后1年、治疗后2年和治疗后3年的基线超声检查。主要观察指标:近距离治疗前、近距离治疗后1年、近距离治疗后2年、近距离治疗后3年的视力、对比敏感度和色觉。结果:19(19)名男性和18名女性，平均年龄58岁(SD 13，范围30-78)，近距离治疗前、治疗后1年、治疗后2年和治疗后3年的平均最佳矫正视力分别为77字母(20/32)、65字母(20/50)、56字母(20/80)和47字母(20/125);对比敏感度为30、26、22、19个字母;色觉分别为26、20、17、14个测试图。近距离治疗后1年、2年和3年的视力、对比敏感度和色觉较基线有统计学意义。3年视力下降与中脉络膜和黄斑黑色素瘤位置、黑色素瘤高度≥4.1 mm、放射性黄斑病变和放射性视神经病变有关。结论:近距离治疗后1、2、3年，CCM患者的视力、对比敏感度和色觉均明显下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Ophthalmology Journal OPHTHALMOLOGY-

CiteScore

0.50

自引率

0.00%

发文量

期刊介绍： The Open Ophthalmology Journal is an Open Access online journal, which publishes research articles, reviews/mini-reviews, letters and guest edited single topic issues in all important areas of experimental and clinical research in ophthalmology, including use of ophthalmological therapies, devices and surgical techniques. The Open Ophthalmology Journal, a peer-reviewed journal, is an important and reliable source of current information on developments in the field. The emphasis will be on publishing quality papers rapidly and making them freely available to researchers worldwide.